Amedisys - AMED Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings or view top-rated stocks.

15 analysts have issued 12-month price targets for Amedisys' shares. Their AMED share price forecasts range from $88.00 to $195.00. On average, they anticipate the company's share price to reach $136.13 in the next twelve months. This suggests a possible upside of 48.8% from the stock's current price.
View analysts price targets for AMED or view top-rated stocks among Wall Street analysts.

Amedisys' stock was trading at $161.88 at the beginning of the year. Since then, AMED shares have decreased by 43.5% and is now trading at $91.50.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our AMED earnings forecast.

Amedisys, Inc. (NASDAQ:AMED) announced its earnings results on Thursday, October, 27th. The health services provider reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.22 by $0.07. The health services provider had revenue of $557.99 million for the quarter, compared to the consensus estimate of $579.30 million. Amedisys had a net margin of 5.45% and a trailing twelve-month return on equity of 16.00%. Amedisys's revenue was up .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.53 earnings per share.

Amedisys declared that its board has authorized a stock repurchase plan on Wednesday, August 4th 2021, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board believes its stock is undervalued.

Amedisys updated its FY22 earnings guidance on Friday, November, 18th. The company provided earnings per share (EPS) guidance of $4.82-4.93 for the period, compared to the consensus earnings per share estimate of $4.84. The company issued revenue guidance of $2.22-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.19%), Vanguard Group Inc. (9.36%), Riverbridge Partners LLC (5.02%), Point72 Asset Management L.P. (3.30%), Mackenzie Financial Corp (3.09%) and State Street Corp (2.68%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends.

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $91.50.

Amedisys (NASDAQ:AMED) has a market capitalization of $2.97 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $3.71 on an earnings per share basis.

The company employs 21,000 workers across the globe.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.